Abstract: This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.

Abstract: Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing vitiligo.

Abstract: Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing vitiligo.

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing an inflammatory skin disease.

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

Abstract: The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

Abstract: This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.

Abstract: The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.

Abstract: The invention generally features compositions and methods for characterizing atopic dermatitis as responsive to anti-Thymic Stromal Lymphopoietin (TSLP) therapy by detecting alterations in the levels of polypeptide and polynucleotide markers present in patient samples, and related treatment methods.

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

Abstract: Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing vitiligo.

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing an inflammatory skin disease.

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

Abstract: The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.

Abstract: An aluminum vehicle carrier railcar has an end door system attached to at least one end of an upper structure thereof including an end door pair, each pivoting about a vertical axis and having an inner and outer door member. The members move from an aligned side-by-side closed position to an open overlapping, nested position exterior and adjacent a railcar side. The members have the same exterior side facing away from the railcar in both the open and the closed positions. A linkage assembly extends from each pivot axis to the members, and each includes a pivotable main arm, an inner arm extending from the main arm to the inner member and an outer arm extending from the main arm to the outer member. Guides extend between the members and between the outer door member and the railcar to guide the relative motion of the members.

Abstract: An aluminum vehicle carrier railcar has an end door system attached to at least one end of an upper structure thereof including an end door pair, each pivoting about a vertical axis and having an inner and outer door member. The members move from an aligned side-by-side closed position to an open overlapping, nested position exterior and adjacent a railcar side. The members have the same exterior side facing away from the railcar in both the open and the closed positions. A linkage assembly extends from each pivot axis to the members, and each includes a pivotable main arm, an inner arm extending from the main arm to the inner member and an outer arm extending from the main arm to the outer member. Guides extend between the members and between the outer door member and the railcar to guide the relative motion of the members.

Abstract: This invention relates to a drink dispensing device, particularly to a device designed for dispensing of particular amounts of water or alternative fluids to an individual, and most particularly to a device which includes a timing function for prompting consumption at programmed intervals.

Abstract: A container (20) suitable for use as a truck box for a pick-up truck, includes a base container portion (21) having an open top, and a cover (22) to close the open top. The cover (22) is pivotally attached to the base (21) by hinge mechanisms (23) which are uniquely formed by combining a hinge pin assembly (101) with a pin retaining assembly (102). The cover (22) may also be latched to the base (21) by a latch assembly (24) which includes pivotable handles (56, 57) on each end of the base (21) which, when either is pivoted, rotates latch hooks (68, 74) from a position engaging the cover (22) to a position releasing the cover, without moving the other handle. The container (20) may also receive a tray (150) therein positionable on a ledge (30) and positively located in one direction by ribs (159) and in the other direction by feet (162) positioned in depressions (38) formed between ribs (37) on the inside of the base (21).